AR004341A1 - Vacunas contra tumores y procedimiento para su produccion. - Google Patents
Vacunas contra tumores y procedimiento para su produccion.Info
- Publication number
- AR004341A1 AR004341A1 ARP960105291A ARP960105291A AR004341A1 AR 004341 A1 AR004341 A1 AR 004341A1 AR P960105291 A ARP960105291 A AR P960105291A AR P960105291 A ARP960105291 A AR P960105291A AR 004341 A1 AR004341 A1 AR 004341A1
- Authority
- AR
- Argentina
- Prior art keywords
- procedure
- production
- vaccines against
- against tumors
- mhc
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 108010039918 Polylysine Proteins 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 102000054766 genetic haplotypes Human genes 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 229920000656 polylysine Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Vacuna contra tumores y procedimiento para su producción. La vacuna contra tumores contiene células tumorales de las que al menos una parte presentapor lo menos un haplotipo MHC-I del paciente en la superficie de la célula y que se cargaron conu no o varios péptidos que se fijan a la molécula de MHC-I,de modo que las células tumorales son reconocidas como extranas en el contexto con los péptidos del sistema inmune del paciente y desencadenan una respuestainmune celular. La carga seefectúa en presencia de un policatión tal como polilisina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19543649A DE19543649C2 (de) | 1995-11-23 | 1995-11-23 | Tumorvakzine und Verfahren zu ihrer Herstellung |
| DE19607044A DE19607044A1 (de) | 1996-02-24 | 1996-02-24 | Tumorvakzine und Verfahren zu ihrer Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR004341A1 true AR004341A1 (es) | 1998-11-04 |
Family
ID=26020603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP960105291A AR004341A1 (es) | 1995-11-23 | 1996-11-22 | Vacunas contra tumores y procedimiento para su produccion. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20020085997A1 (es) |
| EP (1) | EP0866851A1 (es) |
| JP (1) | JP2000502052A (es) |
| KR (1) | KR19990067653A (es) |
| CN (1) | CN1202931A (es) |
| AR (1) | AR004341A1 (es) |
| AU (1) | AU720131B2 (es) |
| BG (1) | BG62999B1 (es) |
| BR (1) | BR9611466A (es) |
| CA (1) | CA2238176A1 (es) |
| CO (1) | CO4520254A1 (es) |
| CZ (1) | CZ158998A3 (es) |
| EE (1) | EE03778B1 (es) |
| HU (1) | HUP0000318A3 (es) |
| NO (1) | NO982329D0 (es) |
| NZ (1) | NZ322910A (es) |
| PL (1) | PL188537B1 (es) |
| RO (1) | RO115275B1 (es) |
| RU (1) | RU2206329C2 (es) |
| SK (1) | SK66998A3 (es) |
| TR (1) | TR199800912T2 (es) |
| TW (1) | TW514530B (es) |
| UY (2) | UY24367A1 (es) |
| WO (1) | WO1997019169A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS50101B (sr) † | 1996-02-24 | 2009-01-22 | Boehringer Ingelheim International Gmbh., | Farmaceutski preparati za imunomodulaciju |
| CA2278678A1 (en) | 1997-01-31 | 1998-08-06 | Research Corporation Technologies, Inc. | Cancer immunotherapy with semi-allogeneic cells |
| EP0904786B1 (en) * | 1997-08-22 | 2004-12-15 | Science Park Raf S.p.A. | Tumor vaccination by use of autologous or HLA-related antigen presenting cell (APC) transduced with a tumour antigen and a foreign antigen capable of causing an immune reaction |
| EP1064390A4 (en) * | 1998-03-20 | 2002-06-12 | Genzyme Corp | Enhanced anti-tumor immunity |
| US7014848B1 (en) | 1998-03-20 | 2006-03-21 | Genzyme Corporation | Enhanced anti-tumor immunity |
| FR2807661A1 (fr) * | 2000-04-14 | 2001-10-19 | Univ Nantes | Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus |
| CA2476995A1 (en) * | 2001-09-18 | 2003-03-27 | Kyogo Itoh | Method of detecting cellular immunity and application thereof to drugs |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| CN1315536C (zh) * | 2002-09-13 | 2007-05-16 | 李进 | 肿瘤抗原疫苗及其制备方法和疫苗组合物 |
| GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| CA2537161C (en) * | 2003-08-25 | 2014-07-29 | Oncomune | Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris) |
| US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
| WO2006105255A2 (en) | 2005-03-29 | 2006-10-05 | The Board Of Trustees Of The University Of Illinois | Cancer vaccines and therapeutic methods |
| DE602005020047D1 (de) * | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| US8765148B2 (en) | 2010-02-19 | 2014-07-01 | Valneva Austria Gmbh | 1C31 nanoparticles |
| CN104662171B (zh) * | 2012-07-12 | 2018-07-13 | 普瑟姆尼股份有限公司 | 个性化癌症疫苗和过继免疫细胞治疗 |
| JP6710004B2 (ja) | 2016-03-15 | 2020-06-17 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計 |
| PE20191842A1 (es) | 2017-05-08 | 2019-12-31 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus |
| CA3140019A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
| JP2023541108A (ja) | 2020-08-06 | 2023-09-28 | グリットストーン バイオ インコーポレイテッド | マルチエピトープワクチンカセット |
| US20240156869A1 (en) * | 2021-03-12 | 2024-05-16 | T-Cure Bioscience, Inc. | Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235525B1 (en) * | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| EP0569678A3 (en) * | 1992-03-13 | 1994-10-26 | Yeda Res & Dev | Double transfectants of MHC genes as cellular vaccines for immunoprevention of tumor metastasis. |
-
1996
- 1996-11-19 UY UY24367A patent/UY24367A1/es not_active IP Right Cessation
- 1996-11-21 CN CN96198493A patent/CN1202931A/zh active Pending
- 1996-11-21 TR TR1998/00912T patent/TR199800912T2/xx unknown
- 1996-11-21 EP EP96939870A patent/EP0866851A1/de not_active Withdrawn
- 1996-11-21 CA CA002238176A patent/CA2238176A1/en not_active Abandoned
- 1996-11-21 SK SK669-98A patent/SK66998A3/sk unknown
- 1996-11-21 WO PCT/EP1996/005126 patent/WO1997019169A1/de not_active Application Discontinuation
- 1996-11-21 HU HU0000318A patent/HUP0000318A3/hu unknown
- 1996-11-21 JP JP9519395A patent/JP2000502052A/ja not_active Abandoned
- 1996-11-21 PL PL96326756A patent/PL188537B1/pl not_active IP Right Cessation
- 1996-11-21 CZ CZ981589A patent/CZ158998A3/cs unknown
- 1996-11-21 RU RU98111622/14A patent/RU2206329C2/ru not_active IP Right Cessation
- 1996-11-21 EE EE9800161A patent/EE03778B1/xx not_active IP Right Cessation
- 1996-11-21 BR BR9611466A patent/BR9611466A/pt not_active Application Discontinuation
- 1996-11-21 AU AU76947/96A patent/AU720131B2/en not_active Ceased
- 1996-11-21 RO RO98-00985A patent/RO115275B1/ro unknown
- 1996-11-21 KR KR1019980703681A patent/KR19990067653A/ko not_active Application Discontinuation
- 1996-11-21 NZ NZ322910A patent/NZ322910A/xx unknown
- 1996-11-21 US US09/077,214 patent/US20020085997A1/en not_active Abandoned
- 1996-11-22 AR ARP960105291A patent/AR004341A1/es not_active Application Discontinuation
- 1996-11-22 CO CO96061701A patent/CO4520254A1/es unknown
- 1996-11-23 TW TW085114455A patent/TW514530B/zh not_active IP Right Cessation
-
1997
- 1997-01-03 UY UY24430A patent/UY24430A1/es not_active IP Right Cessation
-
1998
- 1998-05-08 BG BG102439A patent/BG62999B1/bg unknown
- 1998-05-22 NO NO982329A patent/NO982329D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000502052A (ja) | 2000-02-22 |
| EE03778B1 (et) | 2002-06-17 |
| NZ322910A (en) | 2000-05-26 |
| CZ158998A3 (cs) | 1999-06-16 |
| PL188537B1 (pl) | 2005-02-28 |
| SK66998A3 (en) | 1998-12-02 |
| RU2206329C2 (ru) | 2003-06-20 |
| RO115275B1 (ro) | 1999-12-30 |
| TR199800912T2 (xx) | 1998-08-21 |
| BR9611466A (pt) | 1999-05-18 |
| AU7694796A (en) | 1997-06-11 |
| NO982329D0 (no) | 1998-05-22 |
| KR19990067653A (ko) | 1999-08-25 |
| HUP0000318A3 (en) | 2002-02-28 |
| CA2238176A1 (en) | 1997-05-29 |
| TW514530B (en) | 2002-12-21 |
| PL326756A1 (en) | 1998-10-26 |
| EE9800161A (et) | 1998-12-15 |
| AU720131B2 (en) | 2000-05-25 |
| UY24367A1 (es) | 2000-10-31 |
| EP0866851A1 (de) | 1998-09-30 |
| CN1202931A (zh) | 1998-12-23 |
| CO4520254A1 (es) | 1997-10-15 |
| UY24430A1 (es) | 1997-07-01 |
| BG62999B1 (bg) | 2001-01-31 |
| US20020085997A1 (en) | 2002-07-04 |
| WO1997019169A1 (de) | 1997-05-29 |
| HUP0000318A2 (hu) | 2000-06-28 |
| BG102439A (en) | 1999-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR004341A1 (es) | Vacunas contra tumores y procedimiento para su produccion. | |
| HK1086750A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
| ES2055785T3 (es) | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. | |
| ES2104565T3 (es) | Determinantes anti-receptor de celulas t como tratamiento de enfermedades autoinmunes. | |
| CA2033640A1 (en) | Vaccines against cancer and infectious diseases | |
| DK0742834T4 (da) | Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot celle | |
| TR199800607T1 (xx) | Dendritik h�cre uyar�c� fakt�r�. | |
| HK1142093A1 (en) | Process for the replication of influenza viruses in cell culture, and the influenza viruses obtainable by the process | |
| NO20001768L (no) | Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav | |
| AR003125A1 (es) | Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la | |
| DE69706593D1 (de) | Verwendung von Plasmiden zur Herstellung eines Impfstoffs bei Mensch und Tier | |
| ATE179614T1 (de) | Herpes simplex virus vp16 impfstoffe | |
| ES2186803T3 (es) | Peptidos tio-sustituidos como inhibidores de metaloproteinasas y de la liberacion de tnf. | |
| ES2103854T3 (es) | Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia. | |
| WO2005067460A3 (en) | Epha2 vaccines | |
| NO984052D0 (no) | Rekombinante, adenovirale vektorer for human tumorgenterapi | |
| UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
| RU94040393A (ru) | Синтетические пептиды для вакцины против краснухи | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| PT964697E (pt) | Aplicacoes terapeuticas de antigenios ou epitopos, associados com um processamento celular de peptidos deficiente, e.g. expressos em celulas rma-s transfectadas com um gene b7-1 | |
| SE9903534L (sv) | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning | |
| OA09653A (en) | Rubella peptides | |
| ES2052482T1 (es) | Inhibidora de la proliferacion de celulas endoteliales. | |
| ES8202357A1 (es) | Un procedimiento para preparar una vacuna de virus de la ra-bia inactivados | |
| PT925064E (pt) | 5-androsteno-3beta,17alfa-diol como um inibidor do crescimento tumoral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |